William Blair Reiterates Outperform Rating for Merus (NASDAQ:MRUS)

Merus (NASDAQ:MRUS)‘s stock had its “outperform” rating reaffirmed by William Blair in a research note issued on Friday,RTT News reports. William Blair also issued estimates for Merus’ FY2028 earnings at ($3.58) EPS.

Several other research analysts also recently commented on the stock. Piper Sandler began coverage on shares of Merus in a report on Thursday, February 13th. They issued an “overweight” rating and a $84.00 price objective for the company. Citigroup raised their price objective on shares of Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a report on Monday, December 9th. The Goldman Sachs Group began coverage on shares of Merus in a report on Thursday, November 21st. They issued a “buy” rating and a $73.00 price objective for the company. Guggenheim reaffirmed a “buy” rating on shares of Merus in a report on Wednesday, February 12th. Finally, Wells Fargo & Company began coverage on shares of Merus in a report on Friday, February 7th. They issued an “overweight” rating and a $91.00 price objective for the company. One investment analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $85.77.

Merus Stock Up 1.9 %

Shares of MRUS stock opened at $47.09 on Friday. The company has a 50 day moving average of $42.04 and a 200-day moving average of $46.80. Merus has a 12-month low of $37.77 and a 12-month high of $61.61. The firm has a market cap of $3.22 billion, a P/E ratio of -11.92 and a beta of 1.11.

Merus (NASDAQ:MRUS) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.48. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The company had revenue of $9.14 million during the quarter, compared to analyst estimates of $10.57 million. As a group, equities analysts expect that Merus will post -3.85 EPS for the current year.

Institutional Trading of Merus

Institutional investors and hedge funds have recently made changes to their positions in the stock. State of Wyoming purchased a new stake in shares of Merus during the 4th quarter valued at $48,000. Wells Fargo & Company MN raised its position in shares of Merus by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 300 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Merus during the 4th quarter valued at $60,000. Avior Wealth Management LLC purchased a new stake in shares of Merus during the 4th quarter valued at $76,000. Finally, Lazard Asset Management LLC purchased a new stake in shares of Merus during the 4th quarter valued at $84,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.